Top-Rated StocksTop-RatedNASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $13.09 -0.58 (-4.24%) Closing price 04:00 PM EasternExtended Trading$13.10 +0.02 (+0.11%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Oruka Therapeutics Stock (NASDAQ:ORKA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$12.89▼$13.9050-Day Range$10.90▼$15.5052-Week Range$5.49▼$52.32Volume71,538 shsAverage Volume139,729 shsMarket Capitalization$490.09 millionP/E RatioN/ADividend YieldN/APrice Target$40.38Consensus RatingBuy Company Overview Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. Read More Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 402nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingOruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOruka Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOruka Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ORKA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ORKA. News and Social Media3.4 / 5News Sentiment1.16 News SentimentOruka Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for ORKA on MarketBeat in the last 30 days. MarketBeat Follows9 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.69% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Stock News HeadlinesOruka Therapeutics stock rises after FDA clears IND for psoriasis drugJuly 22, 2025 | investing.comOruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug TrialJuly 22, 2025 | msn.comFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in SeptemberJuly 21, 2025 | globenewswire.comOruka Therapeutics Announces Promotion of Laura Sandler to Oper Chief >ORKAJuly 3, 2025 | marketwatch.comOruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating OfficerJuly 1, 2025 | globenewswire.comORKA Oruka Therapeutics, Inc.May 30, 2025 | seekingalpha.comH.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 TrialMay 27, 2025 | insidermonkey.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $19.39 at the beginning of 2025. Since then, ORKA shares have decreased by 32.5% and is now trading at $13.09. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. Who are Oruka Therapeutics' major shareholders? Top institutional shareholders of Oruka Therapeutics include Geode Capital Management LLC (1.89%), Aberdeen Group plc (0.21%), Intech Investment Management LLC (0.04%) and Police & Firemen s Retirement System of New Jersey (0.02%). View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR). Company Calendar Last Earnings5/14/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.arcabio.com Phone720-940-2100Fax720-208-9261EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Oruka Therapeutics$40.38 High Price Target$49.00 Low Price Target$20.00 Potential Upside/Downside+208.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($4.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.66% Return on Assets-23.39% Debt Debt-to-Equity RatioN/A Current Ratio30.03 Quick Ratio30.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.84 per share Price / Book1.21Miscellaneous Outstanding Shares37,440,000Free Float28,197,000Market Cap$490.09 million OptionableN/A Beta-0.35 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ORKA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.